Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy. | Ann Oncol;8(12): 1277-9, 1997 Dec. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy.

Stewart, D A; Guo, D; Sutherland, J A; Ruether, B A; Jones, A R; Poon, M C; deMetz, C; Klassen, J; Chaudhry, A; Brown, C B; Russell, J A.

Affiliation

Stewart DA; Department of Medical Oncology, Tom Baker Cancer Centre, Foothills Hospital, Calgary, Alberta, Canada.

Ann Oncol ; 8(12): 1277-9, 1997 Dec.

Article in En | MEDLINE | ID: mdl-9496396

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Antineoplastic Agents, Alkylating / Melphalan Type of study: Health_economic_evaluation Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 1997 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Antineoplastic Agents, Alkylating / Melphalan Type of study: Health_economic_evaluation Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 1997 Document type: Article Affiliation country: Country of publication: